Most of the tariff headlines this year focused on the big reciprocal rate resets. The one that actually matters more for corporate margins right now is quieter: the temporary 10% global tariff under Section 122 expired on July 24, and in its place, new Section 301 tariffs kicked in on more than 60 trading partners at 12:01 a.m. Eastern that same day. A few days later, a 100% Section 232 tariff on patented pharmaceutical products and their active ingredients took effect for companies listed in Annex III, starting July 31.

Layered together, this is less a single tariff event than a rolling reset of the cost structure for anyone sourcing goods, components, or drug ingredients from overseas. And unlike the broad, blunt reciprocal tariffs from earlier in the administration, this wave is targeted by trading partner and by product category, which makes the sector-by-sector impact sharper and easier to trace.

Why targeted tariffs hit differently than broad ones

A blanket 10% tariff spreads pain thinly across the whole import base. Section 301 tariffs aimed at specific countries and specific goods concentrate that pain on the companies most exposed to those particular supply chains. Industrials, autos, retail apparel, and metals-intensive manufacturers tend to feel it directly through input costs and sourcing complexity, since they can't easily swap suppliers overnight. Domestic utilities, regional banks, and US-only software names carry far less direct exposure, since their revenue doesn't shrink just because duties rise on goods coming out of a specific trading partner.

The pharmaceutical tariff adds a new wrinkle entirely. A 100% duty on patented drugs and active ingredients for Annex III companies is a materially different cost shock than an apparel tariff, since drug pricing is far stickier and harder to pass through to consumers in the short term. That's a margin story for global pharma manufacturers that analysts are still working through.

It also raises a longer-term question about domestic manufacturing capacity. Tariffs of this size are, in part, meant to push companies toward reshoring active ingredient production and final drug manufacturing onto US soil. That shift doesn't happen in a single quarter. It takes years of capital investment, and in the meantime, the companies most exposed to Annex III sourcing have to absorb the cost somewhere, whether that's compressed margins, higher list prices, or a scramble to requalify alternate suppliers.

The market has mostly shrugged, so far

Despite the volatility tariffs caused earlier in President Trump's second term, the S&P 500's total return has climbed more than 30% since the November 2024 election, and the index is up over 10% year-to-date through late July. That resilience says more about strong earnings and rate expectations elsewhere than it does about tariffs being a non-issue. Legal uncertainty is still a live wildcard here too, since courts have already challenged the legal basis used for the Section 122 tariff, and a reversal could unwind pricing assumptions built into current guidance.

Whitmore's Watchlist:
XLI (Industrial Select Sector SPDR Fund): Broad exposure to the manufacturers most directly touched by rising input costs and sourcing complexity from the new Section 301 duties.
XRT (SPDR S&P Retail ETF): Retailers dependent on imported apparel and goods sit closest to the tariff line among consumer-facing sectors.
UUP (Invesco DB US Dollar Index Bullish Fund): Trade policy shifts move the dollar directly, and the dollar's path shapes how much of this cost gets absorbed domestically versus passed through.

Investors don't need to predict the next legal ruling or the next country added to the list to take something useful from this. The pattern itself is the lesson: tariff policy in 2026 has moved from broad and predictable to narrow and fast-moving, which means the companies most at risk are the ones with concentrated exposure to a handful of trading partners or product categories, not the market as a whole.

That argues for looking at supply chain concentration company by company rather than assuming a sector-wide tariff discount applies evenly. A retailer sourcing broadly across multiple countries is in a very different position than one leaning on a single now-tariffed partner, even if both sit in the same sector index. Earnings calls over the next few quarters are likely to spend more time than usual on supplier diversification and reshoring timelines, simply because that detail now has a direct line to the bottom number.

Whitmore's Take: The tariff story in 2026 isn't a single number anymore, it's a shifting map of exposure by country and product. Worth checking whether the companies you hold have diversified sourcing or a concentrated bet on a single trading partner, since that's now the difference that matters.

Written by Daniel Whitmore
Millionaire Insiders